NCT02661464 - Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo | Biotech Hunter

Enrollment

677

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions

Hemorrhagic Fever, Ebola

Interventions

BIOLOGICAL

Ad26.ZEBOV

No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.

BIOLOGICAL

MVA-BN-Filo

No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.

Trial Locations (16)

Unknown

Rockville

BoboDioulasso

Ouagadougou

Créteil

Paris

Pierre-Bénite

Rennes

Saint-Etienne

Strasbourg

Tours

Nairobi

Mwanza

Entebbe

Kampala

London

Oxford